<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antitumor effects of two anti-CD22 ricin A chain-containing immunotoxin (IT) constructs were compared in mice with <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> disease with human Daudi cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (<z:mp ids='MP_0002536'>SCID</z:mp>-Daudi mice) </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0002536'>SCID</z:mp>-Daudi mice develop disseminated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that clinically resembles African Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, i.e., extranodal disease including infiltration of the vertebral column and spinal canal </plain></SENT>
<SENT sid="2" pm="."><plain>In the absence of treatment, the mean survival time of <z:mp ids='MP_0002536'>SCID</z:mp>-Daudi mice was 45.9 +/- 4.3 days </plain></SENT>
<SENT sid="3" pm="."><plain>The mice was given injections of a dose of IT equal to 40% of the 50% lethal dose </plain></SENT>
<SENT sid="4" pm="."><plain>The ITs consisted of either IgG or Fab' fragments of mouse anti-CD22 antibody coupled to deglycosylated ricin A chain (dgA) </plain></SENT>
<SENT sid="5" pm="."><plain>Both ITs were potent and specific and inhibited protein synthesis in Daudi cells in vitro by 50% at concentrations of 1.2 x 10(-12) (IgG-dgA) and 1.3 x 10(-11) M (Fab'-dgA) </plain></SENT>
<SENT sid="6" pm="."><plain>When administered to mice beginning 1 day after inoculation with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, both ITs extended the mean survival time, to 87.2 +/- 18.9 days (IgG-dgA) or 57.9 +/- 3.8 days (Fab'-dgA) </plain></SENT>
<SENT sid="7" pm="."><plain>The latter represented the killing of 2 logs of Daudi cells, and the former 4 logs </plain></SENT>
<SENT sid="8" pm="."><plain>IgG antibody alone killed 1 log of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>The IgG-dgA had an antitumor effect even when administered 20-23 days after <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inoculation </plain></SENT>
<SENT sid="10" pm="."><plain>Gross and histological examinations of IT-treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice showed a marked decrease in the number and size of neoplastic foci in both lymphoid organs and extranodal sites </plain></SENT>
</text></document>